Lactulose for the Prevention of Hepatic Encephalopathy in Cirrhotic Patients With Upper Gastrointestinal Hemorrhage

• Status: Unknown status
• Trial end date: 2008-11-01
• Target enrollment: 0
• Participant gender: All

Summary

To evaluate the role of lactulose in prevention of clinically overt hepatic encephalopathy (HE) in the setting of acute upper gastrointestinal bleeding in cirrhotic patients

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Aga Khan University
• Treatments: Lactulose

Criteria

Inclusion Criteria:

• Age >18 years

• All acute gastrointestinal bleeding in cirrhotics without hepatic encephalopathy at the time of admission in ER

Exclusion Criteria:

• Increased α-fetoprotein level/ Documented hepatoma

• Portal or hepatic vein thrombosis

• Large-volume or tense ascites requiring repeated therapeutic paracentesis

• Serious recurrent or ongoing co morbid illness (e.g., severe renal, cardiac, or respiratory failure; sepsis)

• Pregnancy

• Not willing to give consent to participate in the study

• Patients who are unable to read and write

• ER arrival time > 12 hrs from index bleed